ProShare Advisors
LYRA

ProShare Advisors’s LYRA THERAPEUTICS INC LYRA Stock Holding History

ProShare Advisors’s Portfolio LYRA Stock Details LYRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-210
Closed -$1.32K – 2141
2025
Q1 		$1.32K Sell
210
-63
-23% -$589 ﹤0.01% 2080
2024
Q4 		$2.81K Buy
+273
New +$3K ﹤0.01% 2270

Other funds holding LYRA

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State of Wisconsin Investment Board
State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ProShare Advisors's LYRA Position: Q2 2025 in Review

ProShare Advisors sold out of LYRA THERAPEUTICS INC (LYRA) in Q2 2025, closing a stake of 210 shares — an estimated $1.32K sold.

ProShare Advisors first reported a position in LYRA in Q4 2024 and held it in 2 quarters. The position peaked at $2.81K in Q4 2024. 30 funds tracked by Wall St. Rank hold LYRA as of Q2 2025.

  • ProShare Advisors reported no remaining LYRA THERAPEUTICS INC position as of Q2 2025 after selling out during the quarter.
  • ProShare Advisors sold 210 LYRA THERAPEUTICS INC shares in Q2 2025, an estimated $1.32K.
  • ProShare Advisors first reported a position in LYRA THERAPEUTICS INC in Q4 2024 and held it in 2 quarters.
  • ProShare Advisors's LYRA THERAPEUTICS INC position peaked at $2.81K in Q4 2024.
  • 30 funds tracked by Wall St. Rank held LYRA THERAPEUTICS INC as of Q2 2025.

Based on ProShare Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.